

CITATION REPORT

List of articles citing

The support of human genetic evidence for approved drug indications

DOI: 10.1038/ng.3314

Nature Genetics, 2015, 47, 856-60.

Source: <https://exaly.com/paper-pdf/62106607/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
930	What does the future hold for cholesteryl ester transfer protein inhibition?. 2015 , 26, 526-35		1
929	Target validation: Genetic information adds supporting weight. 2015 , 14, 525		4
928	Protective alleles and modifier variants in human health and disease. 2015 , 16, 689-701		75
927	Identification of drug candidates and repurposing opportunities through compound-target interaction networks. 2015 , 10, 1333-45		39
926	Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease. 2015 , 35, 2281-9		30
925	Using human genetics to make new medicines. 2015 , 16, 561-2		22
924	Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. 2016 , 13, e1002139		76
923	Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery. 2016 , 17, 414		36
922	Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. 2016 , 17, 212		62
921	The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling. 2016 , 185, 361-71		12
920	'RE:fine drugs': an interactive dashboard to access drug repurposing opportunities. 2016 , 2016,		31
919	Advances in understanding erythropoiesis: evolving perspectives. 2016 , 173, 206-18		59
918	A Landscape of Pharmacogenomic Interactions in Cancer. 2016 , 166, 740-754		892
917	Significant impact of miRNA-target gene networks on genetics of human complex traits. 2016 , 6, 22223		36
916	Disentangling genetic and environmental risk factors for individual diseases from multiplex comorbidity networks. 2016 , 6, 39658		14
915	The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. 2016 , 8, 688-701		96
914	Expanding the Immunology Toolbox: Embracing Public-Data Reuse and Crowdsourcing. 2016 , 45, 1191-1204		13

913	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. 2016 , 23, 681-91	40
912	Drug discovery in focal and segmental glomerulosclerosis. 2016 , 89, 1211-20	11
911	Ovarian Physiology and GWAS: Biobanks, Biology, and Beyond. 2016 , 27, 516-528	9
910	Osteoporosis and Bone Mass Disorders: From Gene Pathways to Treatments. 2016 , 27, 262-281	86
909	Genetic Association-Guided Analysis of Gene Networks for the Study of Complex Traits. 2016 , 9, 179-84	7
908	Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. 2016 , 12, 337-46	36
907	Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. 2016 , 135, 453-467	9
906	A Chemical-Genetic Criterion for Identifying Disease Biomarkers. 2016 , 22, 447-448	1
905	Co-clustering of diseases, genes, and drugs for identification of their related gene modules. 2016 ,	
904	Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. 2016 , 316, 1383-1391	225
903	A Strategy for Genomic Research on Common Cardiovascular Diseases Aiming at the Realization of Precision Medicine: Personal Insights and Perspectives. 2016 , 119, 900-3	4
902	Pediatric Biomedical Informatics. 2016 ,	1
901	Leveraging big data to transform target selection and drug discovery. 2016 , 99, 285-97	105
900	Innovative approaches to bipolar disorder and its treatment. 2016 , 1366, 76-89	57
899	Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us?. 2016 , 25, 251-7	34
898	Trial watch: Impact of genetically supported target selection on R&D productivity. 2016 , 15, 596-597	14
897	A genomics-based systems approach towards drug repositioning for rheumatoid arthritis. 2016 , 17 Suppl 7, 518	12
896	Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. 2016 , 37, 843-857	9

895	Neuroinflammation - using big data to inform clinical practice. 2016 , 12, 685-698	20
894	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. 2016 , 7, 12050	101
893	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. 2016 , 8, 341ra76	77
892	Disciplined approach to drug discovery and early development. 2016 , 8, 349ps15	59
891	The road to precision psychiatry: translating genetics into disease mechanisms. 2016 , 19, 1397-1407	131
890	Translating genome-wide association findings into new therapeutics for psychiatry. 2016 , 19, 1392-1396	86
889	Integrative analysis of cancer genes in a functional interactome. 2016 , 6, 29228	6
888	Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. 2016 , 8, 363ra149	118
887	Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information. 2016 , 22, 2562-2570	8
886	Phenome-based gene discovery provides information about Parkinson's disease drug targets. 2016 , 17 Suppl 5, 493	11
885	Current Concepts of Pharmacogenetics, Pharmacogenomics, and the Druggable Genome. 2016 , 161-183	
884	Precision medicine informatics. 2016 , 23, 668-70	22
883	Pathway and network-based strategies to translate genetic discoveries into effective therapies. 2016 , 25, R94-R98	22
882	Allele-specific transcription factor binding in liver and cervix cells unveils many likely drivers of GWAS signals. 2016 , 107, 248-54	17
881	The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. 2016 , 13, 409-19	65
880	Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery. 2016 , 11, 805-13	8
879	Spatial Colocalization of Human Ohnolog Pairs Acts to Maintain Dosage-Balance. 2016 , 33, 2368-75	24
878	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. 2016 , 30, 59-64	6

877	Health and population effects of rare gene knockouts in adult humans with related parents. 2016 , 352, 474-7		185
876	Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response. 2016 , 27, 31-7		13
875	Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. 2016 , 3, 350-7		77
874	Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. 2016 , 103, 965-78		245
873	The genetics of drug efficacy: opportunities and challenges. 2016 , 17, 197-206		72
872	GWASdb v2: an update database for human genetic variants identified by genome-wide association studies. 2016 , 44, D869-76		118
871	Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection. 2017 , 35, 616-621		3
870	Integrating GWAS and Co-expression Network Data Identifies Bone Mineral Density Genes SPTBN1 and MARK3 and an Osteoblast Functional Module. 2017 , 4, 46-59.e4		66
869	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. 2017 , 7, 41071		27
868	It's all druggable. <i>Nature Genetics</i> , 2017 , 49, 169	36.3	2
867	Osteoarthritis year in review 2016: genetics, genomics and epigenetics. 2017 , 25, 181-189		46
866	Genetic invalidation of Lp-PLA as a therapeutic target: Large-scale study of five functional Lp-PLA-lowering alleles. 2017 , 24, 492-504		16
865	Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. <i>Nature Genetics</i> , 2017 , 49, 416-425	36.3	170
864	Translating Germline Cancer Risk into Precision Prevention. 2017 , 168, 566-570		20
863	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. 2017 , 8, 14175		54
862	Opportunities and challenges of whole-genome and -exome sequencing. 2017 , 18, 14		110
861	Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. 2017 , 15, 113-119		23
860	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. 2017 , 390, 1888-1917		419

859	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. <i>Nature Genetics</i> , 2017 , 49, 946-952	36.3	176
858	STOPGAP: a database for systematic target opportunity assessment by genetic association predictions. 2017 , 33, 2784-2786		24
857	Human genetics as a model for target validation: finding new therapies for diabetes. 2017 , 60, 960-970		15
856	Challenges and progress in interpretation of non-coding genetic variants associated with human disease. 2017 , 242, 1325-1334		20
855	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. 2017 , 14, 577-590		245
854	The genetics revolution in rheumatology: large scale genomic arrays and genetic mapping. 2017 , 13, 421-432		18
853	The impact of rare and low-frequency genetic variants in common disease. 2017 , 18, 77		174
852	Mendelian randomisation in cardiovascular research: an introduction for clinicians. 2017 , 103, 1400-1407		68
851	[Genetic testing in polygenic diseases : Atrial fibrillation, arterial hypertension and coronary artery disease]. 2017 , 42, 440-448		
850	Accelerating the Drug Development Pipeline with Genome-Scale Metabolic Network Reconstructions. 2017 , 139-162		3
849	The druggable genome and support for target identification and validation in drug development. 2017 , 9,		212
848	Open Targets: a platform for therapeutic target identification and validation. 2017 , 45, D985-D994		241
847	Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. 2017 , 100, 40-50		133
846	DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. 2017 , 45, D833-D839		1087
845	Genomic variants, genes, and pathways of Alzheimer's disease: An overview. 2017 , 174, 5-26		101
844	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. 2017 , 5, 869-880		142
843	Genetic and environmental risk factors for chronic kidney disease. 2017 , 7, 88-106		28
842	Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. 2017 , 7, 12460		35

841	Scrutinizing the Genetic Underpinnings of Bone Strength. 2017 , 32, 2147-2150		
840	Genome-wide association studies of cancer: current insights and future perspectives. 2017 , 17, 692-704		173
839	Pharmacogenetics: a general review on progress to date. 2017 , 124, 65-79		26
838	Human genetics contributes to the understanding of disease pathophysiology and drug discovery. 2017 , 22, 977-981		2
837	Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand. 2017 , 76, 2046-2053		42
836	Uncovering novel repositioning opportunities using the Open Targets platform. 2017 , 22, 1800-1807		6
835	Reprint of Editorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. 2017 , 27, 360-362		
834	Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. 2017 ,		85
833	Future Directions of Genomics Research in Rheumatic Diseases. 2017 , 43, 481-487		5
832	Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank. <i>Nature Genetics</i> , 2017 , 49, 1311-1318	36.3	38
831	Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry. 2017 , 20, 1342-1349		85
830	What do polymorphisms tell us about the mechanisms of COPD?. 2017 , 131, 2847-2863		10
829	Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets. 2017 , 21, 2597-2613		71
828	CRISPR/Cas9 for Drug Discovery in Oncology. 2017 , 61-85		1
827	Alzheimer's Disease Genetics and ABCA7 Splicing. 2017 , 59, 633-641		11
826	A Review of Recent Advances in Translational Bioinformatics: Bridges from Biology to Medicine. 2017 , 26, 178-187		12
825	Disease gene classification with metagraph representations. 2017 , 131, 83-92		13
824	10 Years of GWAS Discovery: Biology, Function, and Translation. 2017 , 101, 5-22		1651

823	Genetic modifiers of Mendelian disease: Huntington's disease and the trinucleotide repeat disorders. 2017 , 26, R83-R90	37
822	Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms. 2017 , 170, 199-212.e20	94
821	A New Drug Target for Type 2 Diabetes. 2017 , 170, 12-14	20
820	The Genetics of Skin Aging. 2017 , 537-550	
819	Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. 2017 , 152, 53-67.e3	40
818	Using GWAS to identify novel therapeutic targets for osteoporosis. 2017 , 181, 15-26	28
817	Systemic lupus erythematosus: still a challenge for physicians. 2017 , 281, 52-64	49
816	Gene-based analysis of regulatory variants identifies 4 putative novel asthma risk genes related to nucleotide synthesis and signaling. 2017 , 139, 1148-1157	43
815	Editorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. 2017 , 27, 203-206	
814	From the Data on Many, Precision Medicine for "One": The Case for Widespread Genomic Data Sharing. 2017 , 2, 104-110	7
813	Enhancing the Promise of Drug Repositioning through Genetics. 2017 , 8, 896	40
812	Systematic integration of biomedical knowledge prioritizes drugs for repurposing. 2017 , 6,	151
811	Establishing a reliable framework for harnessing the creative power of the scientific crowd. 2017 , 15, e2001387	8
810	Lifestyle precision medicine: the next generation in type 2 diabetes prevention?. 2017 , 15, 171	33
809	In silico prediction of novel therapeutic targets using gene-disease association data. 2017 , 15, 182	51
808	Whole-exome sequencing in amyotrophic lateral sclerosis suggests NEK1 is a risk gene in Chinese. 2017 , 9, 97	17
807	Challenges in understanding common disease. 2017 , 9, 112	4
806	Translational Education. 2017 , 2, 72-78	

805	Genes, Genomes, and Genomics. 2017 , 1-23	0
804	Genetics in ankylosing spondylitis - Current state of the art and translation into clinical outcomes. 2017 , 31, 763-776	20
803	From here to 2025: Personalised medicine and healthcare for an immediate future. 2018 , 16, 6-21	6
802	Headache Diagnosis in Children and Adolescents. 2018 , 22, 17	15
801	APPLICATIONS OF GENETICS, GENOMICS AND BIOINFORMATICS IN DRUG DISCOVERY. 2018 ,	
800	Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia. 2018 , 175, 674-682	10
799	Executive Function and Genomic Risk for Attention-Deficit/Hyperactivity Disorder: Testing Intermediate Phenotypes in the Context of Polygenic Risk. 2018 , 57, 146-148	3
798	Bridging Information on Drugs, Targets, and Diseases. 2018 , 195-205	
797	Identification of , and as loci associated with systemic lupus erythematosus (SLE) and evaluation of SLE genetics in drug repositioning. 2018 , 77, 1078-1084	16
796	Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. 2018 , 9, 711	35
795	Genetically Validated Drug Targets in Leishmania: Current Knowledge and Future Prospects. 2018 , 4, 467-477	43
794	The central role of DNA damage and repair in CAG repeat diseases. 2018 , 11,	51
793	Evolutionary and genetic features of drug targets. 2018 , 38, 1536-1549	10
792	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. 2018 , 17, 167-181	203
791	Putative functional genes in idiopathic dilated cardiomyopathy. 2018 , 8, 66	6
790	Genetics of immune-mediated inflammatory diseases. 2018 , 193, 3-12	43
789	Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. 2018 , 19, 656-678	48
788	Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets. 2018 , 12, 3	35

787	Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation. 2018 , 122, 1176-1190	15
786	Electronic health records: the next wave of complex disease genetics. 2018 , 27, R14-R21	26
785	Polygenic Risk Scores in Clinical Psychology: Bridging Genomic Risk to Individual Differences. 2018 , 14, 119-157	64
784	Drug repurposing from the perspective of pharmaceutical companies. 2018 , 175, 168-180	155
783	Computational drug repositioning for rare diseases in the era of precision medicine. 2018 , 23, 382-394	43
782	Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. 2018 , 17, 19-33	76
781	Psychiatric Genomics: An Update and an Agenda. 2018 , 175, 15-27	328
780	Ein Instrumentarium von α -RGD-Integrin-Inhibitoren: Wirkstoffsuche, Herausforderungen und Möglichkeiten. 2018 , 130, 3354-3379	12
779	An α -RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities. 2018 , 57, 3298-3321	64
778	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. 2018 , 103, 409-418	26
777	Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. 2018 , 11, 112-122	24
776	Genetic architecture: the shape of the genetic contribution to human traits and disease. 2018 , 19, 110-124	219
775	Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. 2018 , 41, 303-311	13
774	Drug development in the era of precision medicine. 2018 , 17, 183-196	176
773	Discovery of genetic risk factors for disease. 2018 , 48, 191-202	
772	Leveraging Human Genetics to Guide Cancer Drug Development. 2018 , 2, 1-11	1
771	Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. 2018 , 3,	32
770	ERS International Congress 2018: highlights from best-abstract awardees. 2018 , 14, e137-e142	

769	Genotype-Based Recall Studies in Complex Cardiometabolic Traits. 2018 , 11, e001947	2
768	Genetik der koronaren Herzkrankheit. 2018 , 7, 197-203	
767	OBSOLETE: Transcriptome and Epigenome Applications for Coronary Heart Disease Research. 2018	
766	A scientist engineer's contribution to therapeutic discovery and development. 2018 , 243, 1125-1132	1
765	All (animal) models (of neurodegeneration) are wrong. Are they also useful?. 2018 , 215, 2955-2958	33
764	Systematic interrogation of diverse Omic data reveals interpretable, robust, and generalizable transcriptomic features of clinically successful therapeutic targets. 2018 , 14, e1006142	11
763	Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods. 2018 , 23,	9
762	Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders. 2018 , 11, 211-222	17
761	Use of Mendelian randomization for identifying risk factors for brain tumors. 2018 , 9, 525	12
760	Human genes: Time to follow the roads less traveled?. 2018 , 16, e3000034	4
759	A Global Overview of Precision Medicine in Type 2 Diabetes. 2018 , 67, 1911-1922	52
758	Principles of precision medicine and its application in toxicology. 2018 , 43, 565-577	12
757	Human Genome-Wide Association Studies. 2018 , 378-384	
756	Novel Neural Network Approach to Predict Drug-Target Interactions Based on Drug Side Effects and Genome-Wide Association Studies. 2018 , 83, 79-91	
755	Re-thinking Alzheimer's disease therapeutic targets using gene-based tests. 2018 , 37, 461-470	18
754	Phenome-wide association studies across large population cohorts support drug target validation. 2018 , 9, 4285	76
753	Genetic Determinants of IgA Nephropathy: Western Perspective. 2018 , 38, 443-454	15
752	Large-scale investigation of the reasons why potentially important genes are ignored. 2018 , 16, e2006643	107

751	Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. 2018 , 3, 957-966	30
750	Using Mendelian Randomization to Decipher Mechanisms of Bone Disease. 2018 , 16, 531-540	16
749	Cancer expression quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene expression data by modeling variation in tumor purity. 2018 , 19, 130	12
748	Rigor and reproducibility in genetic research on eating disorders. 2018 , 51, 593-607	11
747	Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension. 2018 , 19,	32
746	The impact of genome-wide association studies on biomedical research publications. 2018 , 12, 38	9
745	Genetic-Driven Druggable Target Identification and Validation. 2018 , 34, 558-570	25
744	Prioritising Risk Factors for Type 2 Diabetes: Causal Inference through Genetic Approaches. 2018 , 18, 40	4
743	Next-generation sequencing in drug development: target identification and genetically stratified clinical trials. 2018 , 23, 1776-1783	24
742	The Genetic Background of Neonatal Disease. 2018 , 113, 400-405	4
741	Using Genomic Data to Find Disease-Modifying Loci in Huntington's Disease (HD). 2018 , 1780, 443-461	1
740	Integration of summary data from GWAS and eQTL studies identified novel causal BMD genes with functional predictions. 2018 , 113, 41-48	17
739	Genetics of Bone Fat and Energy Regulation. 2018 , 301-315	
738	Connecting genetics and gene expression data for target prioritisation and drug repositioning. 2018 , 11, 7	12
737	Early Drug Development: Progressing a Candidate Compound to the Clinics. 2018 , 1-8	
736	Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. 2018 , 37, 724-731	16
735	A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017. 2018 , 315, L502-L516	9
734	Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. 2018 , 9, 703	54

733	Recent advances in developing therapeutics for cystic fibrosis. 2018 , 27, R173-R186	24
732	Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. 2018 , 362, k601	576
731	Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis. 2018 , 155, 303-306.e2	34
730	Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. 2018 , 23,	5
729	Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. 2018 , 20, 100	47
728	Genetics of coronary artery disease in the light of genome-wide association studies. 2018 , 107, 2-9	33
727	Data Mining for Systems Biology. 2018 ,	
726	Novel functional variants at the GWAS-implicated loci might confer risk to major depressive disorder, bipolar affective disorder and schizophrenia. 2018 , 19, 22	11
725	Genetic Epidemiology. 2018 ,	
724	Genomic atlas of the human plasma proteome. 2018 , 558, 73-79	529
723	Translating Human Genetics into Novel Drug Targets. 2018 , 1793, 277-290	1
722	Genomic insights into the causes of type 2 diabetes. 2018 , 391, 2463-2474	64
721	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. 2018 , 173, 1705-1715.e16	96
720	Common Disease Is More Complex Than Implied by the Core Gene Omnigenic Model. 2018 , 173, 1573-1580	151
719	Human Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future. 2018 , 11, e002090	41
718	Genetics of Human Aging. 2018 , 1025-1039	
717	Investigating the modulation of genetic effects on late AMD by age and sex: Lessons learned and two additional loci. 2018 , 13, e0194321	14
716	Approaches and advances in the genetic causes of autoimmune disease and their implications. 2018 , 19, 674-684	39

715	The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. 2019 , 108, 57-83	41
714	Rediscovering the value of families for psychiatric genetics research. 2019 , 24, 523-535	30
713	Exocrine or endocrine? A circulating pancreatic elastase that regulates glucose homeostasis. 2019 , 1, 853-855	3
712	A serum protein signature of APOE genotypes in centenarians. 2019 , 18, e13023	11
711	Cohort Profile: Extended Cohort for E-health, Environment and DNA (EXCEED). 2019 , 48, 678-679j	3
710	CDx, NGS and regulation: five perspectives from the Pistoia Alliance. 2019 , 24, 2120-2125	1
709	Use of big data in drug development for precision medicine: an update. 2019 , 4, 189-200	33
708	Psychiatric Genetics Begins to Find Its Footing. 2019 , 176, 609-614	22
707	Pharmacogenomics. 2019 , 394, 521-532	135
706	Pharmacogenes (PGx-genes): Current understanding and future directions. 2019 , 718, 144050	9
705	Towards a Better Classification and Novel Therapies Based on the Genetics of Systemic Sclerosis. 2019 , 21, 44	4
704	Prioritizing target-disease associations with novel safety and efficacy scoring methods. 2019 , 9, 9852	9
703	Integrating Mendelian randomization and multiple-trait colocalization to uncover cell-specific inflammatory drivers of autoimmune and atopic disease. 2019 , 28, 3293-3300	16
702	Integrative analysis of vascular endothelial cell genomic features identifies AIDA as a coronary artery disease candidate gene. 2019 , 20, 133	11
701	Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits. 2019 , 12, 108	5
700	An open science rare diseases research initiative: the University of North Carolina Catalyst. 2019 , 1, FDD6	1
699	A genetics-led approach defines the drug target landscape of 30 immune-related traits. <i>Nature Genetics</i> , 2019 , 51, 1082-1091	36.3 85
698	Priority index for human genetics and drug discovery. <i>Nature Genetics</i> , 2019 , 51, 1073-1075	36.3 15

697	Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study. 2019 , 9, 9386	11
696	Cardiovascular Regenerative Medicine. 2019 ,	3
695	Target 2035: probing the human proteome. 2019 , 24, 2111-2115	62
694	PathFXweb: a web application for identifying drug safety and efficacy phenotypes. 2019 , 35, 4504-4506	2
693	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. 2019 , 179, 736-749.e15	51
692	Predicting translational progress in biomedical research. 2019 , 17, e3000416	25
691	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. 2019 , 10, 4955	46
690	A Review of Genome Wide Association Studies for Erectile Dysfunction. 2019 , 11, 342-347	1
689	Genetic Support for Longevity-Enhancing Drug Targets: Issues, Preliminary Data, and Future Directions. 2019 , 74, S61-S71	1
688	Adhesion G protein-coupled receptors: opportunities for drug discovery. 2019 , 18, 869-884	27
687	Die Rolle seltener Varianten bei häufigen Krankheiten. 2019 , 31, 212-221	1
686	Identifying and Validating New Drug Targets for Stroke and Beyond: Can Mendelian Randomization Help?. 2019 , 140, 831-835	4
685	Leveraging Genetic Findings for Precision Medicine in Vasculitis. 2019 , 10, 1796	5
684	Components of genetic associations across 2,138 phenotypes in the UK Biobank highlight adipocyte biology. 2019 , 10, 4064	26
683	Benchmarking network propagation methods for disease gene identification. 2019 , 15, e1007276	15
682	Atrial Fibrillation Genetics Update: Toward Clinical Implementation. 2019 , 6, 127	15
681	Deconstructing the sources of genotype-phenotype associations in humans. 2019 , 365, 1396-1400	68
680	Translational genomics and precision medicine: Moving from the lab to the clinic. 2019 , 365, 1409-1413	68

679	Editorial: Establishing Genetic Pleiotropy to Identify Common Pharmacological Agents for Common Diseases. 2019 , 10, 1038	1
678	Update on the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond. 2019 , 8,	36
677	The virtuous cycle of human genetics and mouse models in drug discovery. 2019 , 18, 255-272	26
676	Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome. 2019 , 140, 819-830	32
675	Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses. 2019 , 9, 8795	15
674	Combined analysis of keratinocyte cancers identifies novel genome-wide loci. 2019 , 28, 3148-3160	20
673	Interactome Analyses implicated CAMK2A in the genetic predisposition and pharmacological mechanism of Bipolar Disorder. 2019 , 115, 165-175	11
672	Genetic Insights for Drug Development in NAFLD. 2019 , 40, 506-516	34
671	Systems Chemical Genetics-Based Drug Discovery: Prioritizing Agents Targeting Multiple/Reliable Disease-Associated Genes as Drug Candidates. 2019 , 10, 474	8
670	The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. 2019 , 8,	7
669	Moving from one to many: insights from the growing list of pleiotropic cancer risk genes. 2019 , 120, 1087-1089	9
668	Characterising the genetic basis of immune response variation to identify causal mechanisms underlying disease susceptibility. 2019 , 94, 275-284	5
667	Benefits and limitations of genome-wide association studies. 2019 , 20, 467-484	516
666	Predicting human disease mutations and identifying drug targets from mouse gene knockout phenotyping campaigns. 2019 , 12,	12
665	Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. 2019 , 78, 1127-1134	15
664	Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians. 2019 , 9, 7201	10
663	Tissue-specific genes as an underutilized resource in drug discovery. 2019 , 9, 7233	19
662	MicroRNAs and regulation of cardiometabolic phenotypes: novel insights into the complexity of genome-wide association studies loci. 2019 , 115, 1570-1571	0

661	Genome-wide association study of medication-use and associated disease in the UK Biobank. 2019 , 10, 1891	48
660	Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity. 2019 , 177, 597-607.e9	113
659	An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials. 2019 , 106, 841-846	2
658	Genome-Wide Association Studies of Endometrial Cancer: Latest Developments and Future Directions. 2019 , 28, 1095-1102	21
657	Using Human Genetics to Drive Drug Discovery: A Perspective. 2019 , 74, 111-119	5
656	Genetics of Axial Spondyloarthritis. 2019 , 67-85	
655	Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes. 2019 , 28, 2245-2254	23
654	Leveraging brain cortex-derived molecular data to elucidate epigenetic and transcriptomic drivers of complex traits and disease. 2019 , 9, 105	8
653	Genomic Medicine-Progress, Pitfalls, and Promise. 2019 , 177, 45-57	75
652	Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations. 2019 , 31, 69-80	38
651	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. 2019 , 111, 138-147	3
650	Genomic basis of delayed reward discounting. 2019 , 162, 157-161	6
649	GREP: genome for REPositioning drugs. 2019 , 35, 3821-3823	15
648	Mapping causal pathways from genetics to neuropsychiatric disorders using genome-wide imaging genetics: Current status and future directions. 2019 , 73, 357-369	11
647	Platelet Genomics. 2019 , 99-126	
646	Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects. 2019 , 10, 1579	28
645	Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. 2019 , 20, 1123-1134	18
644	An exploratory phenome wide association study linking asthma and liver disease genetic variants to electronic health records from the Estonian Biobank. 2019 , 14, e0215026	5

643	A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data. 2019 , 22, 691-699		62
642	The genetic architecture of osteoporosis and fracture risk. 2019 , 126, 2-10		52
641	Applications of machine learning in drug discovery and development. 2019 , 18, 463-477		558
640	Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities. 2019 , 24, 1232-1236		7
639	Integration of target discovery, drug discovery and drug delivery: A review on computational strategies. 2019 , 11, e1554		16
638	Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. 2019 , 79, 2466-2479		14
637	Predicting clinically promising therapeutic hypotheses using tensor factorization. 2019 , 20, 69		4
636	GWAS and Beyond: Using Omics Approaches to Interpret SNP Associations. 2019 , 7, 30-40		0
635	New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. <i>Nature Genetics</i> , 2019 , 51, 481-493	36.3	156
634	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. <i>Nature Genetics</i> , 2019 , 51, 494-505	36.3	119
633	Genetics of Bone and Muscle Interactions in Humans. 2019 , 17, 86-95		21
632	PheWAS-Based Systems Genetics Methods for Anti-Breast Cancer Drug Discovery. 2019 , 10,		1
631	Using zebrafish to study skeletal genomics. 2019 , 126, 37-50		23
630	Omics in schizophrenia: current progress and future directions of antipsychotic treatments. 2019 , 2, 145-152		1
629	An Active Gene Annotation Corpus and Its Application on Anti-epilepsy Drug Discovery. 2019 ,		3
628	Improving the odds of drug development success through human genomics: modelling study. 2019 , 9, 18911		54
627	. 2019 ,		0
626	A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome. 2019 , 10, 5215		29

625	Pharmacogenomics and Infectious Diseases in Africa. 2019 , 95-127	
624	Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. 2019 , 15, e1008489	152
623	Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. 2019 , 22, 1966-1974	56
622	Chemical Strategies for Evaluating New Drug Targets. 2019 , 1-24	
621	Reverse Translation to Support Efficient Drug Target Selection and Stratified Medicine. 2019 , 153-177	
620	Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. 2019 , 48, 1250-1258	6
619	Medicines discovery for auditory disorders: Challenges for industry. 2019 , 146, 3652	8
618	Genome-wide meta-analysis reveals shared new in systemic seropositive rheumatic diseases. 2019 , 78, 311-319	41
617	Implications of de novo mutations in guiding drug discovery: A study of four neuropsychiatric disorders. 2019 , 110, 83-92	3
616	An atlas of genetic influences on osteoporosis in humans and mice. <i>Nature Genetics</i> , 2019 , 51, 258-266	36.3 270
615	The essentiality of drug targets: an analysis of current literature and genomic databases. 2019 , 24, 544-550	1
614	Dissecting the Genetics of Osteoporosis using Systems Approaches. 2019 , 35, 55-67	25
613	The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. 2019 , 47, D1005-D1012	1422
612	The ORMDL3 Asthma Gene Regulates ICAM1 and Has Multiple Effects on Cellular Inflammation. 2019 , 199, 478-488	45
611	Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence. 2019 , 167, 593-603	9
610	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. 2019 , 70, 19-32	4
609	Quantitative and systems pharmacology 4. Network-based analysis of drug pleiotropy on coronary artery disease. 2019 , 161, 192-204	17
608	Foundations and Application of Precision Medicine. 2019 , 21-45	

607	Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019 , 51, 76-83	177
606	Development of Human Target Validation Classification that Predicts Future Clinical Efficacy. 2019 , 368, 255-261	
605	Novel putative drugs and key initiating genes for neurodegenerative disease determined using network-based genetic integrative analysis. 2019 , 120, 5459-5471	3
604	Eleven loci with new reproducible genetic associations with allergic disease risk. 2019 , 143, 691-699	28
603	Post genome-wide association analysis: dissecting computational pathway/network-based approaches. 2019 , 20, 690-700	4
602	Adding value to real-world data: the role of biomarkers. 2020 , 59, 31-38	8
601	Target discovery using biobanks and human genetics. 2020 , 25, 438-445	2
600	The Longevity-Associated SH2B3 (LNK) Genetic Variant: Selected Aging Phenotypes in 379,758 Subjects. 2020 , 75, 1656-1662	3
599	Genetics of COPD. 2020 , 82, 413-431	36
598	Strengthening Causal Inference for Complex Disease Using Molecular Quantitative Trait Loci. 2020 , 26, 232-241	10
597	Genetic determinants of bone mass and osteoporotic fracture. 2020 , 1615-1630	1
596	The genetics of human ageing. 2020 , 21, 88-101	86
595	Severe Asthma in Children and Adolescents. 2020 ,	
594	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. 2020 , 201, 564-574	81
593	Transcriptome-wide association analysis offers novel opportunities for clinical translation of genetic discoveries on mental disorders. 2020 , 19, 113-114	0
592	A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome. 2020 , 11, 185	27
591	Axes of a revolution: challenges and promises of big data in healthcare. 2020 , 26, 29-38	97
590	A brief history of human disease genetics. 2020 , 577, 179-189	181

589	From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. 2020 , 2, e50-e62	7
588	Identifying cross-disease components of genetic risk across hospital data in the UK Biobank. <i>Nature Genetics</i> , 2020 , 52, 126-134	36.3 22
587	Genetics' Piece of the PI: Inferring the Origin of Complex Traits and Diseases from Proteome-Wide Protein-Protein Interaction Dynamics. 2020 , 42, e1900169	
586	A road map for understanding molecular and genetic determinants of osteoporosis. 2020 , 16, 91-103	85
585	A systems-level framework for anti-epilepsy drug discovery. 2020 , 170, 107868	5
584	A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. 2020 , 11,	1
583	The genetics of asthma and the promise of genomics-guided drug target discovery. 2020 , 8, 1045-1056	33
582	RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice. 2020 , 2, 1113-1125	16
581	The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs. 2020 , 6,	1
580	A guide for bioinformaticians: 'omics-based drug discovery for precision oncology. 2020 , 25, 1897-1897	5
579	Repurposing of medications for pulmonary arterial hypertension. 2020 , 10, 2045894020941494	5
578	Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. 2020 , 40, 2386-2426	25
577	Functional investigation of the coronary artery disease gene SVEP1. 2020 , 115, 67	5
576	The genetics of migraine and the path to precision medicine. 2020 , 255, 403-418	2
575	Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders. 2020 , 11, 556610	2
574	'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. 2020 , 11,	3
573	An Imperative Need for Further Genetic Studies of Alopecia Areata. 2020 , 20, S22-S27	3
572	The Role of Noncoding Variants in Heritable Disease. 2020 , 36, 880-891	25

571	Genetics of Chronic Traumatic Encephalopathy. 2020 , 40, 420-429	2
570	Chances and challenges of machine learning-based disease classification in genetic association studies illustrated on age-related macular degeneration. 2020 , 44, 759-777	3
569	Polygenic inheritance, GWAS, polygenic risk scores, and the search for functional variants. 2020 , 117, 18924-18933	32
568	Leveraging genetic data to investigate molecular targets and drug repurposing candidates for treating alcohol use disorder and hepatotoxicity. 2020 , 214, 108155	
567	Genetic determinants of breast cancer risk. 2020 , 15, 1-7	
566	Calcium Imaging in Drug Discovery for Psychiatric Disorders. 2020 , 11, 713	5
565	Revisiting genome-wide association studies from statistical modelling to machine learning. 2021 , 22,	6
564	Genome-wide pathogenesis interpretation using a heat diffusion-based systems genetics method and implications for gene function annotation. 2020 , 8, e1456	1
563	Using Mendelian randomization to understand and develop treatments for neurodegenerative disease. 2020 , 2, fcaa031	4
562	Advances in Genomics for Drug Development. 2020 , 11,	9
561	AI Enabled Precision Medicine: Patient Stratification, Drug Repurposing and Combination Therapies. 2020 ,	2
560	Tissue-specific genetic features inform prediction of drug side effects in clinical trials. 2020 , 6,	7
559	Genetic Pleiotropy of Bone-Related Phenotypes: Insights from Osteoporosis. 2020 , 18, 606-619	1
558	Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. <i>Nature Genetics</i> , 2020 , 52, 1122-1131	36.3 75
557	PhenomeXcan: Mapping the genome to the phenome through the transcriptome. 2020 , 6,	24
556	The road ahead in genetics and genomics. 2020 , 21, 581-596	43
555	Network and pathway expansion of genetic disease associations identifies successful drug targets. 2020 , 10, 20970	2
554	Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. 2020 , 11, 6417	17

553	Approaching Shared Pathophysiology in Immune-Mediated Diseases through Functional Genomics. 2020 , 11,	2
552	Re-engineering CNS drug discovery and development using computer aided modeling. 2020 , 8, 7	
551	Genetic architecture of host proteins involved in SARS-CoV-2 infection. 2020 , 11, 6397	22
550	Cerebral small vessel disease genomics and its implications across the lifespan. 2020 , 11, 6285	22
549	Functional studies of GWAS variants are gaining momentum. 2020 , 11, 6283	10
548	The Genetic Architecture of High Bone Mass. 2020 , 11, 595653	5
547	Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research. 2020 , 25, 3129-3139	18
546	Genetic underpinnings of cerebral edema in acute brain injury: an opportunity for pathway discovery. 2020 , 730, 135046	2
545	Characterizing the Causal Pathway for Genetic Variants Associated with Neurological Phenotypes Using Human Brain-Derived Proteome Data. 2020 , 106, 885-892	15
544	Evaluating drug targets through human loss-of-function genetic variation. 2020 , 581, 459-464	53
543	Genomics-guided pre-clinical development of cancer therapies.. 2020 , 1, 482-492	9
542	The effect of LRRK2 loss-of-function variants in humans. 2020 , 26, 869-877	47
541	CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets. 2020 , 25, 552-567	6
540	Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery. 2020 , 25, 1174-1190	19
539	Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability. 2020 , 127, 811-823	24
538	Unravelling the complex genetics of common kidney diseases: from variants to mechanisms. 2020 , 16, 628-640	13
537	pyMeSHSim: an integrative python package for biomedical named entity recognition, normalization, and comparison of MeSH terms. 2020 , 21, 252	0
536	Integrating Mouse and Human Genetic Data to Move beyond GWAS and Identify Causal Genes in Cholesterol Metabolism. 2020 , 31, 741-754.e5	16

535	Genomic opportunities for drug repositioning in systemic seropositive rheumatic diseases. 2020 , 16, 343-346	1
534	A common polymorphism in the retinoic acid pathway modifies adrenocortical carcinoma age-dependent incidence. 2020 , 122, 1231-1241	4
533	Update on NAFLD genetics: From new variants to the clinic. 2020 , 72, 1196-1209	85
532	The molecular genetic basis of atrial fibrillation. 2020 , 139, 1485-1498	7
531	Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology. 2020 , 10, 10787	5
530	A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design. 2020 , 10, 1195-1207	3
529	Turning genome-wide association study findings into opportunities for drug repositioning. 2020 , 18, 1639-1650	9
528	Linking protein to phenotype with Mendelian Randomization detects 38 proteins with causal roles in human diseases and traits. 2020 , 16, e1008785	12
527	The multiplex model of the genetics of Alzheimer's disease. 2020 , 23, 311-322	111
526	Genetic Variation and Response to Neurocritical Illness: a Powerful Approach to Identify Novel Pathophysiological Mechanisms and Therapeutic Targets. 2020 , 17, 581-592	1
525	Translational Genomics in Neurocritical Care: a Review. 2020 , 17, 563-580	3
524	Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. 2020 , 43, 567-582	4
523	Precision Medicine in Non-Communicable Diseases. 2020 , 9,	5
522	Next-generation drug repurposing using human genetics and network biology. 2020 , 51, 78-92	35
521	Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. 2020 , 16, 247-264	65
520	Zebrafish models of sarcopenia. 2020 , 13,	8
519	Validity of the cold pressor test and pain sensitivity questionnaire via online self-administration. 2020 , 15, e0231697	4
518	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. 2020 , 15, 1342-1351	1

517	The endless frontier? The recent increase of R&D productivity in pharmaceuticals. 2020 , 18, 162	20
516	Comprehensive Analysis of the Genetic and Epigenetic Mechanisms of Osteoporosis and Bone Mineral Density. 2020 , 8, 194	7
515	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. 2021 , 104, 110050	6
514	Activity- and reactivity-based proteomics: Recent technological advances and applications in drug discovery. 2021 , 60, 20-29	28
513	Genome-wide association of phenotypes based on clustering patterns of hand osteoarthritis identify as novel osteoarthritis gene. 2020 ,	7
512	Platelet Glycoprotein Ib β Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study. 2021 , 73, 693-701	3
511	Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. 2021 , 49, D1311-D1320	49
510	Open Targets Platform: supporting systematic drug-target identification and prioritisation. 2021 , 49, D1302-D1310	56
509	Host genetics and infectious disease: new tools, insights and translational opportunities. 2021 , 22, 137-153	27
508	Implications of new genetic risk factors in prion disease. 2021 , 17, 5-6	1
507	Genomics of hypertension: the road to precision medicine. 2021 , 18, 235-250	34
506	Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome. 2021 , 52, 132-141	15
505	Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms. 2020 ,	10
504	Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets. 2021 , 49, D1365-D1372	13
503	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. 2021 , 99, 926-939	6
502	Systems pharmacology approach uncovers Ligustilide attenuates experimental colitis in mice by inhibiting PPAR β -mediated inflammation pathways. 2021 , 37, 113-128	0
501	Unique roles of rare variants in the genetics of complex diseases in humans. 2021 , 66, 11-23	21
500	Drug repurposing for cancer therapy, easier said than done. 2021 , 68, 123-131	11

499	Challenges and opportunities in rare diseases research. 2021 , 263-284	
498	Genome-wide meta-analysis of pneumonia suggests a role for mucin biology and provides novel drug repurposing opportunities.	1
497	Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. 2021 , 17, e1009224	10
496	Gene-level analysis of rare variants in 363,977 whole exome sequences identifies an association of GIGYF1 loss of function with type 2 diabetes.	3
495	Parameterized algorithms for identifying gene co-expression modules via weighted clique decomposition.. 2021 , 2021, 111-122	1
494	Perspective on Beyond Statistical Significance: Finding Meaningful Effects. 2021 , 7, 1-8	0
493	Searching Far and Genome-Wide: The Relevance of Association Studies in Amyotrophic Lateral Sclerosis. 2020 , 14, 603023	1
492	Mendelian randomization for studying the effects of perturbing drug targets. 2021 , 6, 16	15
491	Introduction to drug discovery. 2021 , 1-13	1
490	CRISPR-Cas9 in cancer therapeutics. 2021 , 181, 129-163	1
489	Computational Drug Target Tractability Analysis. 2021 , 145-153	0
488	An Academic Clinician's Road Map to Hypertension Genomics: Recent Advances and Future Directions MMXX. 2021 , 77, 284-295	4
487	Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome.	
486	Cohort profile: 10K - a large-scale prospective longitudinal study in Israel.	
485	Genetics of eating disorders in the genome-wide era. 2021 , 51, 2287-2297	6
484	Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study. 2021 , 96, e1672-e1679	5
483	Advances in microfluidic in vitro systems for neurological disease modeling. 2021 , 99, 1276-1307	14
482	From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery. 2021 , 12, 624632	5

481	Rare versus common diseases: a false dichotomy in precision medicine. 2021 , 6, 19	1
480	Opportunities and Challenges in Functional Genomics Research in Osteoporosis: Report From a Workshop Held by the Causes Working Group of the Osteoporosis and Bone Research Academy of the Royal Osteoporosis Society on October 5th 2020. 2020 , 11, 630875	2
479	Revealing the role of the human blood plasma proteome in obesity using genetic drivers. 2021 , 12, 1279	14
478	The Interface of Therapeutics and Genomics in Cardiovascular Medicine. 2021 , 35, 663-676	4
477	GW-SEM 2.0: Efficient, Flexible, and Accessible Multivariate GWAS. 2021 , 51, 343-357	4
476	Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates. 2021 , 30, 294-304	3
475	Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. 2021 , 26, 511-524	39
474	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. 2021 , 27, 659-667	52
473	A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. 2021 , 12, 764	27
472	Mendelian randomization for studying the effects of perturbing drug targets. 2021 , 6, 16	11
471	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. 2021 , 18, 435-453	16
470	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. 2021 , 15, 1431-1442	7
469	Cross-platform proteomics to advance genetic prioritisation strategies.	9
468	Genomics-driven drug discovery based on disease-susceptibility genes. 2021 , 41, 8	1
467	Expanding the drug discovery space with predicted metabolite-target interactions. 2021 , 4, 288	1
466	Multi-Modality Machine Learning Predicting Parkinson's Disease.	1
465	Artificial Intelligence-Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development. 2021 , 23, e22453	8
464	Assessing the Function of the Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes. 2021 , 12, 611515	0

463	Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation. 2021 , 34, 108862	12
462	Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches. 2021 , 67, 209-220	1
461	Loss of adipocyte phospholipase gene PLAAT3 causes lipodystrophy and insulin resistance due to inactivated arachidonic acid-mediated PPAR β signaling.	
460	Understanding interactions between risk factors, and assessing the utility of the additive and multiplicative models through simulations. 2021 , 16, e0250282	2
459	Perspectives on Drug Repurposing. 2021 , 28, 2085-2099	8
458	Advancing drug discovery using the power of the human genome. 2021 , 254, 418-429	1
457	System Genetics Including Causal Inference Identify Immune Targets for Coronary Artery Disease and the Lifespan. 2021 , 14, e003196	1
456	Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation.	1
455	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. 2021 , 27, 668-676	19
454	A catalog of GWAS fine-mapping efforts in autoimmune disease. 2021 , 108, 549-563	6
453	Identifying therapeutic drug targets using bidirectional effect genes. 2021 , 12, 2224	3
452	Multi-Ancestry Meta-Analysis yields novel genetic discoveries and ancestry-specific associations.	3
451	Inflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target. 2021 , 160, 1709-1724	12
450	Approval success rates of drug candidates based on target, action, modality, application, and their combinations. 2021 , 14, 1113-1122	3
449	Large-Scale Deep Multi-Layer Analysis of Alzheimer's Disease Brain Reveals Strong Proteomic Disease-Related Changes Not Observed at the RNA Level.	1
448	Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens. 2021 , 28, 2114-2136	2
447	Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications. 2021 , 9, 23	17
446	Estimating colocalization probability from limited summary statistics. 2021 , 22, 254	2

445	Dissecting polygenic signals from genome-wide association studies on human behaviour. 2021 , 5, 686-694		7
444	10K: a large-scale prospective longitudinal study in Israel. 2021 , 36, 1187-1194		0
443	Identification of Novel Genomic-Variant Patterns of OR56A5, OR52L1, and CTSD in Retinitis Pigmentosa Patients by Whole-Exome Sequencing. 2021 , 22,		1
442	Integrated Role of Nanotechnology and Pharmacogenetics in Diagnosis and Treatment of Diseases.		
441	Utilizing graph machine learning within drug discovery and development. 2021 , 22,		18
440	Precision Medicine Approaches to Vascular Disease: JACC Focus Seminar 2/5. 2021 , 77, 2531-2550		3
439	MCGA: a multi-strategy conditional gene-based association framework integrating with isoform-level expression profiles reveals new susceptible and druggable candidate genes of schizophrenia.		
438	Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). 2021 , 1		4
437	Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. <i>Nature Genetics</i> , 2021 , 53, 962-971	36.3	28
436	Association of Antihypertensive Drug Target Genes With Psychiatric Disorders: A Mendelian Randomization Study. 2021 , 78, 623-631		0
435	Genetic Susceptibility to Pneumonia: A GWAS Meta-Analysis Between the UK Biobank and FinnGen. 2021 , 24, 145-154		0
434	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. 2021 , 46, 1821-1829		5
433	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. 2021 , 30, 1669-1680		2
432	Genome editing to define the function of risk loci and variants in rheumatic disease. 2021 , 17, 462-474		3
431	Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline. 247553032110260		
430	Using "-omics" Data to Inform Genome-wide Association Studies (GWASs) in the Osteoporosis Field. 2021 , 19, 369-380		0
429	Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. 2021 , 3, 100284		7
428	Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. <i>Nature Genetics</i> , 2021 , 53, 942-948	36.3	42

427	Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms.	0
426	Tumor necrosis factor- β gene polymorphism is associated with short- and long-term kidney allograft outcomes..	0
425	A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. 2021 , 48, 49-88	9
424	Human gene function publications that describe wrongly identified nucleotide sequence reagents are unacceptably frequent within the genetics literature.	1
423	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. 2021 , 24, 1302-1312	9
422	Sequencing of 640,000 exomes identifies variants associated with protection from obesity. 2021 , 373,	22
421	Genetics in Drug Discovery. 2021 , 37, 603-605	
420	Challenges and Opportunities in Understanding Genetics of Fungal Diseases: Towards a Functional Genomics Approach. 2021 , 89, e0000521	1
419	Efficacy of computational predictions of the functional effect of idiosyncratic pharmacogenetic variants. 2021 , 9, e11774	1
418	Network expansion of genetic associations defines a pleiotropy map of human cell biology.	0
417	Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury. 2021 , 74, 3394-3408	0
416	Genetic Investigation of Inverse Psoriasis. 2021 , 11,	2
415	A functional TGFB1 polymorphism in the donor associates with long-term graft survival after kidney transplantation.	0
414	Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. 2021 , 2021, 9945725	2
413	Advancing the use of genome-wide association studies for drug repurposing. 2021 , 22, 658-671	12
412	A KCNK16 mutation causing TALK-1 gain of function is associated with maturity-onset diabetes of the young. 2021 , 6,	3
411	An integrative network-based approach for drug target indication expansion. 2021 , 16, e0253614	3
410	Genetic Prioritization, Therapeutic Repositioning and Cross-Disease Comparisons Reveal Inflammatory Targets Tractable for Kidney Stone Disease. 2021 , 12, 687291	1

409	Molecular genetics of cocaine use disorders in humans. 2021,	3
408	Mendelian Randomization in Stroke: A Powerful Approach to Causal Inference and Drug Target Validation. 2021, 12, 683082	1
407	Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome. 2021, 10,	1
406	Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis. 2021, 13,	2
405	Assigning function to SNPs: Considerations when interpreting genetic variation. 2021, 121, 135-135	1
404	Mapping the genetic architecture of human traits to cell types in the kidney identifies mechanisms of disease and potential treatments. <i>Nature Genetics</i> , 2021, 53, 1322-1333	36.3 7
403	Enhancers in disease: molecular basis and emerging treatment strategies. 2021, 27, 1060-1073	4
402	AI models and the future of genomic research and medicine: True sons of knowledge?: Artificial intelligence needs to be integrated with causal conceptions in biomedicine to harness its societal benefits for the field. 2021, 43, e2100025	0
401	Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation. 2021, 11, 16483	3
400	Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease (NAFLD) : A systematic review. 2021, 1	1
399	The "GENomics of Musculo Skeletal Traits Translational Network": Origins, Rationale, Organization, and Prospects. 2021, 12, 709815	2
398	Mendelian Randomization: Concepts and Scope. 2021,	16
397	Multitrait GWAS to connect disease variants and biological mechanisms. 2021, 17, e1009713	1
396	Rare variant contribution to human disease in 281,104 UK Biobank exomes. 2021, 597, 527-532	17
395	Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria. 2021, 28, 1221-1234.e6	2
394	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. 2021, 70, 103521	5
393	From variant to function in human disease genetics. 2021, 373, 1464-1468	11
392	Integrative Network-Based Analysis Reveals Gene Networks and Novel Drug Repositioning Candidates for Alzheimer Disease. 2021, 7, e622	2

391	Human inducible pluripotent stem cells: Realization of initial promise in drug discovery. 2021 , 28, 1507-1515	4
390	Using Human Genetics to Understand Mechanisms in Ischemic Stroke Outcome: From Early Brain Injury to Long-Term Recovery. 2021 , 52, 3013-3024	2
389	Emerging therapeutic opportunities for integrin inhibitors. 2021 ,	30
388	Implications of genetic variation in the complement system in age-related macular degeneration. 2021 , 84, 100952	10
387	Clinical Functional Genomics. 2021 , 13,	0
386	Novel characterization of the multivariate genetic architecture of internalizing psychopathology and alcohol use. 2021 , 186, 353-366	0
385	Integrative Neuroinformatics for Precision Prognostication and Personalized Therapeutics in Moderate and Severe Traumatic Brain Injury. 2021 , 12, 729184	0
384	Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response. 2021 , 22,	0
383	A functional polymorphism in the donor associates with long-term graft survival after kidney transplantation.. 2022 , 15, 278-286	2
382	Study of effect modifiers of genetically predicted CETP reduction.	
381	CRISPR screens identify gene targets and drug repositioning opportunities at breast cancer risk loci.	
380	Stroke Genetics: Turning Discoveries into Clinical Applications. 2021 , 52, 2974-2982	0
379	VannoPortal: multiscale functional annotation of human genetic variants for interrogating molecular mechanism of traits and diseases. 2021 ,	3
378	Functional interrogation of autoimmune disease genetics using CRISPR/Cas9 technologies and massively parallel reporter assays. 2021 , 1	2
377	Repurposing Cardio-Metabolic Drugs to Fight Covid19. 2021 , 28, 419-423	1
376	Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation. 2021 , 187, 106573	1
375	An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. 2021 , 60, 170-176	3
374	Genetic ablation of Gpnmb does not alter synuclein-related pathology. 2021 , 159, 105494	0

373	Genetics of Asthma: Insights From Genome Wide Association Studies. 2022 , 308-325		
372	The evolution and history of gene editing technologies. 2021 , 178, 1-62		2
371	Genetics and Drug Discovery. 2021 , 251-266		1
370	Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal. 2021 , 17, 185-192		6
369	Proteome-wide Systems Genetics to Identify Functional Regulators of Complex Traits. 2021 , 12, 5-22		6
368	Integrative Omics Reveal Novel Protein Targets For Chronic Obstructive Pulmonary Disease Biomarker Discovery.		0
367	Multi-omics analyses of cognitive traits and psychiatric disorders highlights brain-dependent mechanisms. 2021 ,		4
366	Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles.		2
365	MendelVar: gene prioritization at GWAS loci using phenotypic enrichment of Mendelian disease genes. 2021 , 37, 1-8		4
364	Human genome diversity data reveal that L564P is the predominant TPC2 variant and a prerequisite for the blond hair associated M484L gain-of-function effect. 2021 , 17, e1009236		7
363	Chemogenomics for drug discovery: clinical molecules from open access chemical probes. 2021 , 2, 759-795		2
362	Epidemiology of Dementia: The Burden on Society, the Challenges for Research. 2018 , 1750, 3-14		25
361	Phenotypic Screening of iPSC-Derived Cardiomyocytes for Cardiotoxicity Testing and Therapeutic Target Discovery. 2019 , 19-34		1
360	Genetics of Osteosarcopenia. 2019 , 215-230		3
359	Genetic Determinants and Pharmacogenetics of Osteoporosis and Osteoporotic Fracture. 2020 , 485-506		3
358	Genetic architecture of common non-Alzheimer's disease dementias. 2020 , 142, 104946		16
357	Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. <i>Nature Genetics</i> , 2017 , 49, 1468-1475	36.3	235
356	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. <i>Nature Genetics</i> , 2018 , 50, 524-537	36.3	536

355	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. 2020 , 76, 842-850	2
354	Genome-wide association study identifies 17 new loci influencing concentrations of circulating cytokines and growth factors.	2
353	MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations.	77
352	Systematic integration of biomedical knowledge prioritizes drugs for repurposing.	1
351	Pathways analyses of schizophrenia GWAS focusing on known and novel drug targets.	6
350	When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders.	1
349	Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank.	3
348	Novel blood pressure locus and gene discovery using GWAS and expression datasets from blood and the kidney.	1
347	Psychiatric Genomics: An Update and an Agenda.	3
346	Consequences of natural perturbations in the human plasma proteome.	10
345	Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer's Disease.	8
344	Identifying therapeutic drug targets for rare and common forms of short stature.	1
343	Regional differences in reported Covid-19 cases show genetic correlations with higher socio-economic status and better health, potentially confounding studies on the genetics of disease susceptibility.	3
342	Multi-omics study revealing putative drug targets of COVID-19 severity and other viral infection diseases.	7
341	Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.	5
340	Genetic susceptibility to pneumonia: A GWAS meta-analysis between UK Biobank and FinnGen.	4
339	Multitrait genetic-phenotype associations to connect disease variants and biological mechanisms.	3
338	An Effector Index to Predict Causal Genes at GWAS Loci.	3

337	Genetic architecture of host proteins interacting with SARS-CoV-2. 2020,	5
336	Open Targets Genetics: An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci.	10
335	A Neanderthal OAS1 isoform Protects Against COVID-19 Susceptibility and Severity: Results from Mendelian Randomization and Case-Control Studies.	4
334	Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank.	12
333	Single-cell dissection of schizophrenia reveals neurodevelopmental-synaptic axis and transcriptional resilience.	5
332	Mapping the genetic architecture of human traits to cell types in the kidney identifies mechanisms of disease and potential treatments.	1
331	Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.	1
330	Surveying the contribution of rare variants to the genetic architecture of human disease through exome sequencing of 177,882 UK Biobank participants.	4
329	Phenome-wide association studies (PheWAS) across large real-world data population cohorts support drug target validation.	5
328	Predicting clinically promising therapeutic hypotheses using tensor factorization.	3
327	Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects.	4
326	Enrichment of rare protein truncating variants in amyotrophic lateral sclerosis patients.	4
325	An Atlas of Human and Murine Genetic Influences on Osteoporosis.	3
324	New genetic signals for lung function highlight pathways and pleiotropy, and chronic obstructive pulmonary disease associations across multiple ancestries.	5
323	Large-scale whole-genome sequencing of three diverse Asian populations in Singapore.	3
322	Benchmarking network propagation methods for disease gene identification.	1
321	pyMeSHSim: an integrative python package for biomedical named entity recognition, normalization and comparison.	2
320	Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.	9

319	Evaluating potential drug targets through human loss-of-function genetic variation.	12
318	The fog of genetics: Known unknowns and unknown unknowns in the genetics of complex traits and diseases.	1
317	Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson's disease.	7
316	A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome.	2
315	A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits.	13
314	Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.	21
313	Proteome-by-phenome Mendelian Randomisation detects 38 proteins with causal roles in human diseases and traits.	0
312	Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis.	0
311	Immune disease variants modulate gene expression in regulatory CD4+ T cells and inform drug targets.	4
310	The Endless Frontier? The Recent Upsurge of R&D Productivity in Pharmaceuticals.	1
309	Target Gene Notebook: Connecting genetics and drug discovery.	1
308	Identification of putative effector genes across the GWAS Catalog using molecular quantitative trait loci from 68 tissues and cell types.	3
307	Exploration of the role of CHRNA5-A3-B4 genotype in smoking behaviours.	1
306	PhenomeXcan: Mapping the genome to the phenome through the transcriptome.	6
305	Chances and challenges of machine learning based disease classification in genetic association studies illustrated on age-related macular degeneration.	1
304	Multomics dissection of molecular regulatory mechanisms underlying autoimmune-associated noncoding SNPs. 2020 , 5,	4
303	Novel biomarkers for cardiovascular risk prediction. 2017 , 14, 135-150	109
302	Using regulatory genomics data to interpret the function of disease variants and prioritise genes from expression studies. 2018 , 7, 121	2

301	Assessing drug target suitability using TargetMine. 2019 , 8, 233	2
300	SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets. 2020 , 9, 992	5
299	Meta-analysis of exome array data identifies six novel genetic loci for lung function. 3, 4	6
298	Meta-analysis of exome array data identifies six novel genetic loci for lung function. 3, 4	1
297	Meta-analysis of exome array data identifies six novel genetic loci for lung function. 2018 , 3, 4	16
296	Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C. 2016 , 11, e0166923	20
295	Phenome-wide association study using research participants' self-reported data provides insight into the Th17 and IL-17 pathway. 2017 , 12, e0186405	14
294	The fog of genetics: what is known, unknown and unknowable in the genetics of complex traits and diseases. 2019 , 20, e48054	7
293	Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. 2020 , 16, e9405	22
292	e2 and aging-related outcomes in 379,000 UK Biobank participants. 2020 , 12, 12222-12233	23
291	The role of genomics and genetics in pulmonary arterial hypertension. 2020 , 2020, e202013	3
290	Pharmacogenetics and Depression: A Critical Perspective. 2019 , 16, 645-653	9
289	COVID-19 research risks ignoring important host genes due to pre-established research patterns. 2020 , 9,	7
288	Priority index: database of genetic targets in immune-mediated disease. 2021 ,	2
287	AI for drug discovery is advancing rapidly: We need smart biology for it to fulfill its mission. 2021 , 27, 1-1	0
286	Research Priorities for Kidney-Related Research-An Agenda to Advance Kidney Care: A Position Statement From the National Kidney Foundation. 2021 ,	2
285	A Network-based Deep Learning Framework Catalyzes GWAS and Multi-Omics Findings to Biology and Drug Repurposing for Alzheimer's Disease.	
284	Growth Factors and Their Roles in Multiple Sclerosis Risk. 2021 , 12, 768682	0

283	Improving ethnic diversity in respiratory genomics research. 2021 , 58,	0
282	Human Genomics and Drug Development. 2021 ,	2
281	A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment. 2021 ,	2
280	Workshop proceedings: GWAS summary statistics standards and sharing. 2021 , 1, 100004	4
279	Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.	
278	A trans-omic Mendelian randomization study of parental lifespan uncovers novel aging biology and therapeutic candidates for chronic diseases. 2021 , 20, e13497	1
277	Genetic associations of protein-coding variants in human disease.	1
276	Multi-tissue transcriptome-wide association study identifies eight candidate genes and tissue-specific gene expression underlying endometrial cancer susceptibility. 2021 , 4, 1211	2
275	The Genetics of Skin Aging. 2015 , 1-14	
274	Application of Genomics to the Study of Human Growth Disorders. 2016 , 363-384	
273	Pathway and network-based strategies to translate genetic discoveries into effective therapies.	
272	The impact of genome-wide association studies on biomedical research publications.	1
271	Causal analyses, statistical efficiency and phenotypic precision through Recall-by-Genotype study design.	2
270	A question of fate. 2017 , 15, e2002329	1
269	Meta-analysis of exome array data identifies six novel genetic loci for lung function.	
268	Flipping the odds of drug development success through human genomics.	
267	Systematic interrogation of diverse Omic data reveals interpretable, robust, and generalizable transcriptomic features of clinically successful therapeutic targets.	
266	Disease Gene Classification with Metagraph Representations. 2018 , 1807, 211-224	3

265 Transcriptome and Epigenome Applications for Coronary Heart Disease Research. **2018**, 572-581

264 Matching drug transcriptional signatures to rare losses disrupting synaptic gene networks identifies known and novel candidate drugs for schizophrenia.

263 Using regulatory genomics data to interpret the function of disease variants and prioritise genes from expression studies. **2018**, 7, 121

1

262 Integrating Mendelian randomization and multiple-trait colocalization to uncover cell-specific inflammatory drivers of autoimmune and atopic disease.

261 Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities.

260 Cohort Profile: Extended Cohort for E-health, Environment and DNA (EXCEED).

0

259 The Genetic Sphygmomanometer: an argument for routine genome-wide genotyping in the population and a new view on its use to inform clinical practice. **2018**, 3, 138

258 Tissue-specific genes as an underutilized resource in drug discovery.

0

257 Genetic analyses of medication-use and implications for precision medicine.

256 Frontiers in Precision Medicine IV: Artificial Intelligence, Assembling Large Cohorts, and the Population Data Revolution.

255 Assessing drug target suitability using TargetMine. **2019**, 8, 233

1

254 Systematic phenomics analysis of ASD-associated genes reveals shared functions and parallel networks underlying reversible impairments in habituation learning.

1

253 Leveraging genetic data to investigate molecular targets and drug repurposing candidates for treating alcohol use disorder and hepatotoxicity.

252 Validity of the Cold Pressor Test and Pain Sensitivity Questionnaire via online self-administration.

251 Genomics and Pharmacogenomics of Severe Childhood Asthma. **2020**, 313-341

250 Dissecting molecular regulatory mechanisms underlying noncoding susceptibility SNPs associated with 19 autoimmune diseases using multi-omics integrative analysis.

249 Genetics of (Premature) Coronary Artery Disease. **2020**, 413-430

248 Genomische Variation. **2020**, 49-67

- 247 A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease. 0
- 246 Estimating colocalization probability from limited summary statistics.
- 245 An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. *Nature Genetics*, **2021**, 53, 1527-1533 36.3 22
- 244 Genetics and Pharmacogenetics of COPD. **2020**, 39-55
- 243 Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.
- 242 Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology.
- 241 TiMEG: an integrative approach for partially missing multi-omics data with an application to tuberous sclerosis.
- 240 Multi-tissue transcriptome-wide association study identifies genetic mechanisms underlying endometrial cancer susceptibility.
- 239 Clinical pharmacogenetics. **2022**, 189-212
- 238 Antisense oligonucleotide drugs for neurological and neuromuscular disease. **2020**, 221-245
- 237 A novel mutation inKCNK16causing a gain-of-function in the TALK-1 potassium channel: a new cause of maturity onset diabetes of the young.
- 236 ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants. 1
- 235 Identifying Nootropic Drug Targets via Large-Scale Cognitive GWAS and Transcriptomics. 0
- 234 MendelVar: gene prioritization at GWAS loci using phenotypic enrichment of Mendelian disease genes. 0
- 233 Network and pathway expansion of genetic disease associations identifies successful drug targets.
- 232 Integrative genomics analysis of eQTL and GWAS summary data identifies PPP1CB as a novel bone mineral density risk genes. **2020**, 40,
- 231 Network-Driven Drug Discovery. **2022**, 2390, 177-190
- 230 Gene-level analysis of rare variants in 379,066 whole exome sequences identifies an association of GIGYF1 loss of function with type 2 diabetes. **2021**, 11, 21565 2

229	Deletion of gene locus exacerbates neuropathological features of Alzheimer's disease in a mouse model of Aβ amyloidosis. 2021 , 7, eabe3954		4
228	Pairwise effects between lipid GWAS genes modulate lipid plasma levels and cellular uptake. 2021 , 12, 6411		0
227	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021 , 53, 1543-1552	36.3	11
226	Predicting novel candidate human obesity genes and their site of action by systematic functional screening in <i>Drosophila</i> . 2021 , 19, e3001255		0
225	Integration of innovative statistical methods using genetic data provides pharmacological insight and facilitates drug development. 2021 ,		
224	The genetic architecture of medication-use.		0
223	Pairwise genetic interactions modulate lipid plasma levels and cellular uptake.		
222	Genetic study of circulating cytokines offers insight into the determinants, cascades and effects of systemic inflammation.		1
221	An integrative multi-omics analysis of 16 autoimmune diseases and cancer outcomes highlights immune-cell regulatory mechanisms and shared genetic architecture.		1
220	Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease. 2015 , 2015, 1851-60		14
219	Drug repositioning for prostate cancer: using a data-driven approach to gain new insights. 2017 , 2017, 1724-1733		1
218	Recent advances in lung cancer genomics: Application in targeted therapy. 2021 , 108, 201-275		0
217	Genetic regulation of RNA splicing in human pancreatic islets.		0
216	GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy.		
215	Photo-Switchable Sulfonyleureas Binding to ATP-Sensitive Potassium Channel Reveal the Mechanism of Light-Controlled Insulin Release. 2021 , 125, 13111-13121		1
214	Intersecting single-cell transcriptomics and genome-wide association studies identifies crucial cell populations and candidate genes for atherosclerosis.		
213	Anti-Irritant Strategy against Retinol Based on the Genetic Analysis of Korean Population: A Genetically Guided Top-Down Approach.. 2021 , 13,		0
212	Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. 2021 , 12, 6822		5

211	Integration of Real-World Data and Genetics to Support Target Identification and Validation. 2021 , 111, 63	0
210	Combining Human Genetics of Multiple Sclerosis with Oxidative Stress Phenotype for Drug Repositioning.. 2021 , 13,	0
209	Large-scale sequencing studies expand the known genetic architecture of Alzheimer's disease.. 2021 , 13, e12255	
208	Genetics of common cerebral small vessel disease.. 2022 ,	2
207	Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease.. 2022 , 17, 3	1
206	Genetics and Epigenetics in Allergic Rhinitis.. 2021 , 12,	4
205	Short structural variants as informative genetic markers for ALS disease risk and progression.. 2022 , 20, 11	0
204	Identification of Drug Transporter Genomic Variants and Inhibitors that Protect Against Doxorubicin-Induced Cardiotoxicity. 2021 ,	5
203	Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes.. 2021 , 12, 719791	0
202	Immune targets for therapeutic development in depression: towards precision medicine.. 2022 ,	5
201	Identification of human gene research articles with wrongly identified nucleotide sequences.. 2022 , 5,	1
200	Translating osteoarthritis genetics research: challenging times ahead.. 2022 ,	0
199	Fine mapping with epigenetic information and 3D structure.. 2022 , 44, 115	0
198	Genomic Variation. 2022 , 49-65	
197	Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.. 2022 , 14, 7	3
196	Integrative analysis of 3604 GWAS reveals multiple novel cell type-specific regulatory associations.. 2022 , 23, 13	1
195	Clinical Utility of Genomic Testing in Cancer Care.. 2022 , 6, e2100349	4
194	How Genetics Can Improve Clinical Practice in Chronic Kidney Disease: From Bench to Bedside.. 2022 , 12,	0

193	Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension.. 2022 , 13, 46		5
192	Pregnancy, Preeclampsia and Maternal Aging: From Epidemiology to Functional Genomics. 2021 , 73, 101535		1
191	Gene-based polygenic risk scores analysis of alcohol use disorder in African Americans.		
190	The characteristics of early-stage research into human genes are substantially different from subsequent research.. 2022 , 20, e3001520		2
189	Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models.. 2022 , 13,		0
188	Multi-omics research in sarcopenia: Current progress and future prospects.. 2022 , 76, 101576		4
187	An effector index to predict target genes at GWAS loci.. 2022 , 1		0
186	Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles.. <i>Nature Genetics</i> , 2022 , 54, 152-160	36.3	13
185	A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis.		2
184	Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.. 2021 , 1, 1175-1188		13
183	Loss of sucrase-isomaltase function increases acetate levels and improves metabolic health in Greenlandic cohorts.. 2021 ,		1
182	Intersecting single-cell transcriptomics and genome-wide association studies identifies crucial cell populations and candidate genes for atherosclerosis.. 2022 , 2, oead043		2
181	Multi-Ancestry Mendelian Randomization of Omics Traits Revealing Putative Drug Targets of COVID-19 Severity.		
180	Improving mouse models for the study of Alzheimer's disease.. 2022 , 148, 79-113		
179	Multi-ancestry Genome-wide Association Study of Varicose Veins Reveals Polygenic Architecture, Genetic Overlap with Arterial and Venous Disease, and Novel Therapeutic Opportunities.		
178	Hypertension Pharmacogenomics in CKD: The Clinical Relevance and Public Health Implications.. 2022 , 3, 204-207		0
177	Genetic associations of protein-coding variants in human disease.. 2022 , 603, 95-102		5
176	Genetic Predisposition and the Variable Course of Infectious Diseases.. 2022 ,		0

- 175 Using Genomic data to Investigate the Anti-Depressive Effects of Statins.
- 174 Pooled CRISPR KO Screens for Target Identification. **2022**, 113-125
- 173 Genome-wide analysis of longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis.
- 172 Genomic Evidence Supports the Recognition of Endometriosis as an Inflammatory Systemic Disease and Reveals Disease-Specific Therapeutic Potentials of Targeting Neutrophil Degranulation.. **2022**, 13, 758440 0
- 171 Evaluating the potential benefits and pitfalls of combining protein and expression quantitative trait loci in evidencing drug targets.
- 170 Evaluating a causal relationship between Complement Factor I protein level and advanced age-related macular degeneration using Mendelian Randomisation. **2022**, 100146 0
- 169 Pharmacogenomics: relevance and opportunities for clinical pharmacology.. **2022**, 1 1
- 168 Optimizing translational research for exceptional health and life span: A systematic narrative of studies to identify translatable therapeutic target(s) for exceptional health span in humans.. **2022**,
- 167 Using causal methods to map symptoms to brain circuits in neurodevelopment disorders: moving from identifying correlates to developing treatments.. **2022**, 14, 19 0
- 166 Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics.. **2022**, 101603 2
- 165 Candidates for Drug Repurposing to Address the Cognitive Symptoms in Schizophrenia.
- 164 Immune disease variants modulate gene expression in regulatory CD4 T_H cells.. **2022**, 2, None 0
- 163 Multi-modality machine learning predicting Parkinson's disease.. **2022**, 8, 35 1
- 162 Organisation of gene programs revealed by unsupervised analysis of diverse gene-trait associations.
- 161 Tumor Necrosis Factor- α Gene Polymorphism is Associated with Short- and Long-Term Kidney Allograft Outcomes.. **2022**, 15, 2243-2254 1
- 160 Inhibiting thyroid activation in aged human explants prevents mechanical induced detrimental signalling by mitigating metabolic processes.. **2022**,
- 159 Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.. **2022**, 7, 28 0
- 158 The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases.. **2022**, 15, 74 1

157	dbTMM: an integrated database of large-scale cohort, genome and clinical data for the Tohoku Medical Megabank Project. 2021 , 8, 44	1
156	TiMEG: an integrative statistical method for partially missing multi-omics data.. 2021 , 11, 24077	0
155	Integration of GWAS and brain transcriptomic analyses in a multiethnic sample of 35,245 older adults identifies DCDC2 gene as predictor of episodic memory maintenance. 2021 ,	1
154	Gene Signature-Based Drug Repositioning.	
153	Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias.. 2021 ,	0
152	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.. 2021 , 12, 7342	2
151	Starring role of Biomarkers and Anticancer Agents as a Major Driver in Precision Medicine of Cancer Therapy.. 2021 ,	
150	SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics. 2022 , 171-260	0
149	Stroke Genetics: Discovery, Insight Into Mechanisms, and Clinical Perspectives.. 2022 , 130, 1095-1111	2
148	Suppression of Somatic Expansion As a Novel Therapeutic Approach for Huntington Disease and Other Repeat Expansion Disorders. 2022 , 1, 163-175	
147	A conditional gene-based association framework integrating isoform-level eQTL data reveals new susceptibility genes for schizophrenia.. 2022 , 11,	1
146	Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder.. 2022 ,	7
145	Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomization study.	0
144	Integrative Multi-Omics database (iMOMdb) of Asian Pregnant Women.. 2022 ,	0
143	Table_1.xlsx. 2019 ,	
142	Image_1.PNG. 2020 ,	
141	Table_1.XLSX. 2020 ,	
140	Table_2.XLSX. 2020 ,	

139	Table_3.XLSX. 2020,	
138	Table_4.XLSX. 2020,	
137	Coming of Age: Human Genomics and the Cancer-Immune Set Point.. 2022, OF1-OF6	0
136	OUP accepted manuscript.	0
135	OUP accepted manuscript.	0
134	A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. 2022, 12, 669	
133	Pharmacogenomics for the efficacy and side effects of antihistamines.. 2022,	2
132	The genetic basis for adult onset glaucoma: Recent advances and future directions.. 2022, 101066	1
131	Linking GWAS to pharmacological treatments for psychiatric disorders.	
130	Whole-exome sequencing study identifies novel rare variants and genes associated with intraocular pressure and glaucoma.	
129	How genetic risk contributes to autoimmune liver disease.	0
128	A Mendelian randomization study investigating the causal role of inflammation on Parkinson disease.	1
127	Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials.	
126	Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants.	2
125	Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. 2022, 5,	1
124	A novel "social contract" An attempt to harmonize a sponsor's exploratory research with a clinical study participant's data rights. 2022, 119, 106819	
123	DSEATM: drug set enrichment analysis uncovering disease mechanisms by biomedical text mining. 2022, 23,	0
122	Computational estimation of quality and clinical relevance of cancer cell lines. 2022, 18,	0

121	Multi-ancestry Mendelian randomization of omics traits revealing drug targets of COVID-19 severity. 2022 , 81, 104112	
120	Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform. 1-10	0
119	A cross-species approach using an in vivo evaluation platform in mice demonstrates that sequence variation in the human RABEP2 gene modulates ischemic stroke outcomes.	
118	Translational impact of omics studies in alopecia areata: recent advances and future perspectives. 1-13	1
117	Drug re-engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery.	1
116	Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease. 2022 , 1-19	
115	Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. 2022 , 1-26	3
114	Gene-based polygenic risk scores analysis of alcohol use disorder in African Americans. 2022 , 12,	0
113	GEARS: Predicting transcriptional outcomes of novel multi-gene perturbations.	0
112	Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. 2022 , 23, 7508	
111	Genetic determinants of fungi-induced ROS production are associated with the risk of invasive pulmonary aspergillosis. 2022 , 55, 102391	0
110	Germline Mutations in CIDEB and Protection against Liver Disease. 2022 , 387, 332-344	1
109	Exploiting gene dependency to inform drug development for multiple myeloma. 2022 , 12,	
108	Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study.	1
107	Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity. 2022 , 13,	0
106	Putative Candidate Drug Targets for Sarcopenia-Related Traits Identified Through Mendelian Randomization Analysis of the Blood Proteome. 13,	1
105	Bridging the splicing gap in human genetics with long-read RNA sequencing: finding the protein isoform drivers of disease.	1
104	Anticipating Pharmacological Perturbation With Human Genetic Variation Lessons From CETP.	

103	A systems biology-based identification and in vivo functional screening of Alzheimer's disease risk genes reveals modulators of memory function.	
102	Novel functional genomics approaches bridging neuroscience and psychiatry. 2022 ,	0
101	Association between Human Blood Metabolome and the Risk of Alzheimer's Disease.	0
100	An Overview of Methods and Exemplars of the Use of Mendelian Randomisation in Nutritional Research. 2022 , 14, 3408	1
99	Scalable approaches for functional analyses of whole-genome sequencing non-coding variants.	
98	An efficient and robust tool for colocalisation: Pair-wise Conditional and Colocalisation (PWCoCo).	0
97	Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. 2022 , 13,	0
96	Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study. 2022 ,	0
95	Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma.	
94	Genetics of multiple sclerosis: lessons from polygenicity. 2022 , 21, 830-842	2
93	Network analysis of genome-wide association studies for drug target prioritisation. 2022 , 71, 102206	0
92	Genomic Approaches for Drug Repositioning. 2022 , 49-72	0
91	Polypharmacology in Drug Design and DiscoveryBasis for Rational Design of Multitarget Drugs. 2022 , 397-533	0
90	Target Discovery for Drug Development Using Mendelian Randomization. 2022 , 1-20	0
89	The heritability and molecular genetics of mental disorders. 2022 ,	0
88	Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. 2022 , 54, 1275-1283	2
87	Effects of Coronary Artery DiseaseAssociated Variants on Vascular Smooth Muscle Cells. 2022 , 146, 917-929	1
86	Using genome-wide association results to identify drug repurposing candidates.	0

- 85 The genetic overlap between osteoporosis and craniosynostosis. 13, 1
- 84 Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk. 0
- 83 Association Between Human Blood Metabolome and the Risk of Psychiatric Disorders. 0
- 82 Candidates for drug repurposing to address the cognitive symptoms in schizophrenia. **2022**, 110637 0
- 81 Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. 0
- 80 Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies. **2022**, 109, 1638-1652 0
- 79 The grand challenge of discovering new cardiovascular drugs. 2, 0
- 78 Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation. **2022**, 0
- 77 Drug repurposing candidates to treat core symptoms in autism spectrum disorder. 13, 0
- 76 The common IL1A SNP rs17561 is a hypomorphic mutation that significantly reduces IL -1 β release from human blood cells. 0
- 75 Genetic regulation of RNA splicing in human pancreatic islets. **2022**, 23, 0
- 74 A resource for integrated genomic analysis of the human liver. **2022**, 12, 0
- 73 Ten challenges for clinical translation in psychiatric genetics. **2022**, 54, 1457-1465 1
- 72 Predictive validity in drug discovery: what it is, why it matters and how to improve it. 4
- 71 A cross-species approach using an *in vivo* evaluation platform in mice demonstrates that sequence variation in human RABEP2 modulates ischemic stroke outcomes. **2022**, 109, 1814-1827 0
- 70 Sex-dependent placental mQTL provide insight into the prenatal origins of childhood-onset traits and conditions. 0
- 69 Harnessing AI and Genomics to Accelerate Drug Discovery. **2022**, 89-106 0
- 68 A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis. 0

- 67 A genomic deep field view of hypertension. **2022**, ○
- 66 Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. **2022**, 12, ○
- 65 Statistical methods for cis -Mendelian randomization with two-sample summary-level data. ○
- 64 An Overview of Gene Variants of Endothelin-1: A Critical Regulator of Endothelial Dysfunction. ○
- 63 Using human genetics to improve safety assessment of therapeutics. ○
- 62 Alternative splicing in the lung influences COVID-19 severity and respiratory diseases. ○
- 61 A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. **2022**, 2, 100190 ○
- 60 On the way to translate GWAS into kidney disease mechanisms. **2022**, ○
- 59 Developing clinically translatable screens using iPSC-derived neural cells. **2023**, 265-287 ○
- 58 The role of gene×ambient air pollution interactions in paediatric asthma. **2022**, 31, 220094 ○
- 57 Polygenic risk scores: An overview from bench to bedside for personalised medicine. 13, 1
- 56 Prioritization of drug targets for neurodegenerative diseases by integrating genetic and proteomic data from brain and blood. **2022**, ○
- 55 The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. ○
- 54 Whole-exome sequencing study identifies rare variants and genes associated with intraocular pressure and glaucoma. **2022**, 13, 1
- 53 Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer’s disease. **2022**, 41, 111717 ○
- 52 Identifying Genetic Variants and Metabolites Associated with Rapid Estimated Glomerular Filtration Rate Decline in Korea Based on Genome×Metabolomic Integrative Analysis. **2022**, 12, 1139 ○
- 51 Identifying novel proteins underlying schizophrenia via integrating pQTLs of the plasma, CSF, and brain with GWAS summary data. **2022**, 20, ○
- 50 Genetic and Multi-omic Risk Assessment of Alzheimer’s Disease Implicates Core Associated Biological Domains. ○

49	Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100. 2023 , 15, 28	1
48	The module triad: a novel network biology approach to utilize patients' multi-omics data for target discovery in ulcerative colitis. 2022 , 12,	1
47	A multiple sclerosis-protective coding variant reveals an essential role for HDAC7 in regulatory T cells. 2022 , 14,	1
46	An interleukin 6-based genetic risk score strengthened with interleukin 10 polymorphisms associated with long-term kidney allograft outcomes. 2022 , 22, 45-57	0
45	Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery. 9,	0
44	Leveraging a Billion-Edge Knowledge Graph for Drug Re-purposing and Target Prioritization using Genomically-Informed Subgraphs.	0
43	The Human Genome Is Not Enough. 2023 , 43, 37-39	0
42	Genetics of varicose veins reveals polygenic architecture and genetic overlap with arterial and venous disease. 2023 , 2, 44-57	0
41	A systems biology approach identifies the role of dysregulated PRDM6 in the development of hypertension.	0
40	New drugs and targets in the GWAS era of bipolar disorder.	0
39	Examining the shared etiology of psychopathology with genome-wide association studies.	0
38	Identification of potential causal metabolites associated with atopic dermatitis.	0
37	The genetic architecture of changes in adiposity during adulthood.	0
36	COVID-19 host genetics and ABO blood group susceptibility. 1-24	0
35	Molecular Landscape of Tourette Disorder. 2023 , 24, 1428	0
34	New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications. 2023 , 22, 4-24	0
33	Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery. 2023 , 63, 65-76	0
32	Study of effect modifiers of genetically predicted CETP reduction.	0

31	Pharmacogenomics: current status and future perspectives.	0
30	Association between human blood metabolome and the risk of breast cancer. 2023 , 25,	0
29	Drug Repurposing in Cancer. 2023 , 159-179	0
28	Mendelian randomization as a tool to inform drug development using human genetics. 2023 , 1,	0
27	Novel insight into the etiology of ischemic stroke gained by integrative transcriptome-wide association study.	0
26	Proteomic analysis of 92 circulating proteins and their effects in cardiometabolic diseases.	0
25	CRISPR screens identify gene targets at breast cancer risk loci. 2023 , 24,	0
24	Future prospects for human genetics and genomics in drug discovery. 2023 , 80, 102568	0
23	Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis. 14,	1
22	Using genetic association data to guide drug discovery and development: Review of methods and applications. 2023 , 110, 195-214	0
21	Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort. 3,	0
20	Why Clinical Trials Stop: The Role of Genetics.	0
19	Using human genetics to validate complement C3 as a drug target in periodontitis.	0
18	Network expansion of genetic associations defines a pleiotropy map of human cell biology. 2023 , 55, 389-398	0
17	New Genetic Insights in Rheumatoid Arthritis using Taxonomy3D , a Novel method for Analysing Human Genetic Data.	0
16	Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism.	0
15	Challenges in systemic lupus erythematosus: From bench to bedside. 2023 , 293-331	0
14	The genetic architecture of pain intensity in a sample of 598,339 U.S. veterans.	0

- 13 The genetic architecture of pain intensity in a sample of 598,339 U.S. veterans. ○
- 12 Multi-layered genetic approaches to identify approved drug targets. ○
- 11 The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases. 12, ○
- 10 Predicting ExWAS findings from GWAS data: a shorter path to causal genes. ○
- 9 Male-pattern hair loss: Comprehensive identification of the associated genes as a basis for understanding pathophysiology. **2023**, 35, 3-14 ○
- 8 Precision medicine in systemic lupus erythematosus. ○
- 7 10 Years of GWAS in intraocular pressure. 14, ○
- 6 Repurposing antidiabetic drugs for rheumatoid arthritis: results from a two-sample Mendelian randomization study. ○
- 5 Multi-omic underpinnings of epigenetic aging and human longevity. **2023**, 14, ○
- 4 Wrestling with Social and Behavioral Genomics: Risks, Potential Benefits, and Ethical Responsibility. **2023**, 53, ○
- 3 Single-cell genomics meets human genetics. ○
- 2 Association of asthma genetic variants with asthma-associated traits reveals molecular pathways of eosinophilic asthma. **2023**, 13, ○
- 1 Idiopathic Pulmonary Fibrosis. **2023**, 104166 ○